Storia in 2 fonti

AbCellera, Silence and InduPro all raise significant funding

AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro closes $77M Series B.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

AbCellera, Silence and InduPro all raise significant funding

AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro closes $77M Series B.

originale

biopharmadive.com1 g fa

Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

Leggi questa versione → originale

Timeline cronologica

mercoledì 12 agosto 2026·biopharmadive.com
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera…
mercoledì 12 agosto 2026·endpoints.news
AbCellera, Silence and InduPro all raise significant funding
AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro closes $77M Series B.